Medicare Part D plans' coverage and cost-sharing for acute rescue and preventive inhalers for chronic obstructive pulmonary disease

JAMA Internal Medicine

Volumn 177, Issue 4, 2017, Pages 585-588

  Tseng, Chien Wen ^a   Yazdany, Jinoos ^b   Dudley, R Adams ^b   DeJong, Colette ^b   Kazi, Dhruv S ^c   Chen, Randi ^d   Lin, Grace A ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PACIFIC HEALTH RESEARCH AND EDUCATION INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; ARFORMOTEROL; BECLOMETASONE; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; FLUTICASONE; FLUTICASONE FUROATE PLUS VILANTEROL; FORMOTEROL; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; INDACATEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; LEVALBUTEROL; MOMETASONE FUROATE; PROCATEROL; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; TIOTROPIUM BROMIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG COST; HEALTH CARE COST; HUMAN; INHALER; LETTER; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICARE; PRIORITY JOURNAL; COST; ECONOMICS; MEDICATION COMPLIANCE; NEBULIZER; UNITED STATES;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; COST SHARING; HUMANS; MEDICARE; MEDICARE PART D; MEDICATION ADHERENCE; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UNITED STATES;

EID: 85018559774     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2016.9386     Document Type: Letter

References (6)

1. Han MK, Martinez CH, Au DH, et al. Meeting the challenge of COPD care delivery in the USA: A multiprovider perspective. Lancet Respir Med. 2016;4(6): 473-526. Published online May 13, 2016.
2. Ford ES. Hospital discharges, readmissions, and ED visits for COPD or bronchiectasis among US adults: Findings from the nationwide inpatient sample 2001-2012 and Nationwide Emergency Department Sample 2006-2011. Chest. 2015;147(4):989-998.
3. Health IndicatorsWarehouse. Chronic obstructive pulmonary disease (COPD) Medicare beneficiaries (percent). http://www.healthindicators.gov /Indicators/Chronic-obstructive-pulmonary-disease-COPD-Medicare -beneficiaries-percent-290/Profile/ClassicData. Accessed October 12, 2016.
4. Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged 18 years in the United States for 2010 and projections through 2020. Chest. 2015;147(1):31-45.
5. Castaldi PJ, Rogers WH, Safran DG, Wilson IB. Inhaler costs and medication nonadherence among seniors with chronic pulmonary disease. Chest. 2010;138 (3):614-620.
6. Jena AB, Ho O, Goldman DP, Karaca-Mandic P. The impact of the US Food and Drug Administration chlorofluorocarbon ban on out-of-pocket cost and use of albuterol inhalers among individuals with asthma. JAMA Intern Med. 2015; 175(7):1171-1179.